AbbVie Inc. Net Debt/EBITDA

Net Debt/EBITDA of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt/EBITDA growth rates and interactive chart.


Highlights and Quick Summary

  • Net Debt/EBITDA for the quarter ending September 29, 2019 was 8.9 (a 9.0% increase compared to previous quarter)
  • Year-over-year quarterly Net Debt/EBITDA decreased by -155.14%
  • Annual Net Debt/EBITDA for 2019 was 0.0 (a -100.0% decrease from previous year)
  • Annual Net Debt/EBITDA for 2018 was 3.96 (a 58.53% increase from previous year)
  • Annual Net Debt/EBITDA for 2017 was 2.5 (a -13.58% decrease from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt/EBITDA of AbbVie Inc.

Most recent Net Debt/EBITDAof ABBV including historical data for past 10 years.

Interactive Chart of Net Debt/EBITDA of AbbVie Inc.

AbbVie Inc. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 8.9 8.16 9.09 0.0
2018 -16.13 8.83 10.41 8.31 3.96
2017 12.82 9.19 9.88 11.04 2.5
2016 11.51 11.02 11.15 9.16 2.89
2015 9.8 10.83 11.19 3.98 2.78
2014 -29.74 3.88 2.62 3.42 1.57
2013 2.78 3.25 3.55 4.93 0.74
2012 3.61 -2.52 -0.04 -0.03 1.1
2011 0.11 0.0 0.0 0.0 -0.12
2010 0.0 -0.0
2009 0.0

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.